Cargando…

Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells

Triple negative breast cancer is a collection of heterogeneous breast cancers that are immunohistochemically negative for estrogen receptor, progesterone receptor, and ErbB2 (due to deletion or lack of amplification). No dominant proliferative driver has been identified for this type of cancer, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Jinyan, Li, Li, Howlett, Niall G., Cohen, Paul S., Sun, Gongqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281712/ https://www.ncbi.nlm.nih.gov/pubmed/32349331 http://dx.doi.org/10.3390/cancers12051087

Ejemplares similares

Biphasic Mathematical Model of Cell–Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells
por: Shen, Jinyan, et al.
Publicado: (2020)

Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells
por: Shen, Jinyan, et al.
Publicado: (2019)

Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
por: Chapdelaine, Abygail G., et al.
Publicado: (2023)

Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells
por: Ku, Geng Chia, et al.
Publicado: (2022)

Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice
por: Zhang, Tian, et al.
Publicado: (2017)

Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer
por: Nadesh, Ragima, et al.
Publicado: (2021)

Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020)

Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells
por: Wang, Yi, et al.
Publicado: (2022)

Repurposing of drugs for triple negative breast cancer: an overview
por: Spini, Andrea, et al.
Publicado: (2020)

Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021)

What Does It Take to Synergistically Combine Sub-Potent Natural Products into Drug-Level Potent Combinations?
por: Qin, Chu, et al.
Publicado: (2012)

Author Correction: Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer
por: Nadesh, Ragima, et al.
Publicado: (2023)

A potent tumoricidal co-drug ‘Bet-CA' - an ester derivative of betulinic acid and dichloroacetate selectively and synergistically kills cancer cells
por: Saha, Suchandrima, et al.
Publicado: (2015)

SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
por: Geng, Wenwen, et al.
Publicado: (2023)

Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer
por: Colavito, Sierra A., et al.
Publicado: (2019)

Approach to the Triple Negative Breast Cancer in New Drugs Area
por: Mirzania, Mehrzad
Publicado: (2016)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
por: Abu Bakar, Nur Fitriyani Afiqah Binti, et al.
Publicado: (2023)

A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature
por: El-Sahli, Sara, et al.
Publicado: (2021)

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells
por: Bajor, Malgorzata, et al.
Publicado: (2020)

Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells
por: Dasari, Venkata Ramesh, et al.
Publicado: (2020)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

TGF-β induced reprogramming and drug resistance in triple-negative breast cells
por: Wu, Guoyu, et al.
Publicado: (2022)

Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer
por: Shin, Sung-Young, et al.
Publicado: (2018)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

Expression pattern analysis and drug differential sensitivity of cancer-associated fibroblasts in triple-negative breast cancer
por: Li, Qilong, et al.
Publicado: (2020)

Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer
por: Khanna, Vidhi, et al.
Publicado: (2019)

Triple-negative breast cancer: understanding Wnt signaling in drug resistance
por: Merikhian, Parnaz, et al.
Publicado: (2021)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
por: Masci, Domiziana, et al.
Publicado: (2023)

Biphasic Activity of Chloroquine in Human Colorectal Cancer Cells
por: Park, Deokbae, et al.
Publicado: (2014)

The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer
por: Li, Jing, et al.
Publicado: (2023)

Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells
por: Sooman, Linda, et al.
Publicado: (2017)

Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells
por: Peronne, Lauralie, et al.
Publicado: (2020)

Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells
por: Ovejero-Sánchez, María, et al.
Publicado: (2022)

EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
por: Xia, Lin, et al.
Publicado: (2020)

Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
por: Wang, Tianduanyi, et al.
Publicado: (2020)

Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer
por: Mehdizadeh, Reza, et al.
Publicado: (2021)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iardp5ko1sc5nm75oe6ae88ta2